Vesikansa, Aino
Mehtälä, Juha
Jokelainen, Jari
Mutanen, Katja
Lundqvist, Annamari
Laatikainen, Tiina
Ylisaukko-oja, Tero
Saukkonen, Tero
Pietiläinen, Kirsi H.
Funding for this research was provided by:
novo nordisk
Article History
Accepted: 4 September 2021
First Online: 17 September 2021
Declarations
:
: TY is the owner of MedEngine Oy. AV, JM, and JJ are employees of MedEngine Oy. TS and KM are employees of Novo Nordisk and TS owns shares in Novo Nordisk. KP has lectured for the following pharmaceutical companies: AstraZeneca, MSD, Novo Nordisk, Sanofi, participated in advisory boards for IKEA, Novo Nordisk, Takeda, Vivus, and has received independent research grants from the following foundations: the Academy of Finland (Grant Nos. 272376, 314383, 266286); Finnish Medical Foundation; Gyllenberg Foundation; Finnish Diabetes Research Foundation; Sigrid Juselius Foundation; Novo Nordisk Foundation (Grant Nos. NNF17OC0027232, NNF10OC1013354); University of Helsinki and Government Research Funds through Helsinki University Hospital. TL and AL have no competing interests.
: The FinHealth 2017 Survey received approval from the Coordinating Ethics Committee at the Hospital District of Helsinki and Uusimaa (Ref 37/13/03/00/2016). This study was based on existing data collected in the FinHealth study complemented with data from the nationwide registers, and no new ethics approval was required. All data used in the analyses were pseudonymous, and the permission to use the FinHealth 2017 data for this study was granted by the THL Biobank.
: All FinHealth 2017 study participants had filled informed consent for a biobank study.